Urogen Pharma (URGN)
(Delayed Data from NSDQ)
$13.78 USD
+0.81 (6.25%)
Updated May 15, 2024 04:00 PM ET
After-Market: $13.73 -0.05 (-0.36%) 7:58 PM ET
4-Sell of 5 4
F Value A Growth B Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
URGN 13.78 +0.81(6.25%)
Will URGN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for URGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for URGN
Pharming Group (PHAR) Surges 7.2%: Is This an Indication of Further Gains?
Urogen Pharma (URGN) Reports Q4 Loss, Tops Revenue Estimates
URGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Nurix Therapeutics, Inc. (NRIX) Surges 5.1%: Is This an Indication of Further Gains?
ADC Therapeutics SA (ADCT) Reports Q3 Loss, Lags Revenue Estimates
UroGen Pharma (URGN) Stock Surges 89% in a Month: Here's Why
Other News for URGN
UroGen Pharma price target lowered by $2 at Oppenheimer, here's why
Urogen Pharma (URGN) Gets a Buy from Oppenheimer
UroGen Pharma Holds Steady Amidst Financial Underperformance and Anticipated Study Results
Buy Rating Affirmed for Urogen Pharma as UGN-102 Progresses Towards FDA Approval and Market Success
UroGen Pharma Ltd (URGN) Q1 2024 Earnings Call Transcript Highlights: Key Financials and ...